| Year |
Citation |
Score |
| 2024 |
Nathan DM, Lachin JM. History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes. Diabetes Care. PMID 39083683 DOI: 10.2337/dci24-0063 |
0.475 |
|
| 2024 |
Latres E, Greenbaum CJ, Oyaski ML, Dayan CM, Colhoun HM, Lachin JM, Skyler JS, Rickels MR, Ahmed ST, Dutta S, Herold KC, Marinac M. Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes. PMID 38349844 DOI: 10.2337/dbi23-0012 |
0.312 |
|
| 2024 |
Braffett BH, El Ghormli L, Albers JW, Feldman EL, Herman WH, Gubitosi-Klug RA, Martin CL, Orchard TJ, White NH, Lachin JM, Perkins BA, Pop-Busui R. Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes. Diabetes Care. PMID 38300889 DOI: 10.2337/dc23-1749 |
0.686 |
|
| 2023 |
Sinha Gregory N, Burghardt AJ, Backlund JC, Rubin MR, Bebu I, Braffett BH, Kenny DJ, Link TM, Kazakia GJ, Barnie A, Lachin JM, Gubitosi-Klug R, de Boer IH, Schwartz AV. Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-Standing Type 1 Diabetes. Diabetes Care. PMID 38029518 DOI: 10.2337/dc23-0839 |
0.69 |
|
| 2023 |
Khatri M, Ryan CM, Gao X, de Boer IH, Braffett BH, Molitch M, Karger AB, Lorenzi GM, Lee P, Trapani VR, Lachin JM, Jacobson AM. Chronic Kidney Disease Associates with Cognitive Decline in Middle-aged and Older Adults with Long-standing Type 1 Diabetes. Kidney360. PMID 37291722 DOI: 10.34067/KID.0000000000000178 |
0.651 |
|
| 2022 |
Lachin JM, Bebu I, Gao X, Nathan DM, Zinman B. Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448. Diabetes Care. 46: e13. PMID 36548707 DOI: 10.2337/dci22-0040 |
0.398 |
|
| 2022 |
Bebu I, Braffett BH, de Boer IH, Aiello LP, Bantle JP, Lorenzi GM, Herman WH, Gubitosi-Klug RA, Perkins BA, Lachin JM, Molitch ME. Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: the DCCT/EDIC Study. Diabetes Care. PMID 36520643 DOI: 10.2337/dc22-1744 |
0.705 |
|
| 2022 |
Perkins BA, Bebu I, de Boer IH, Molitch M, Zinman B, Bantle J, Lorenzi GM, Nathan DM, Lachin JM. Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes. Diabetes Care. PMID 36321737 DOI: 10.2337/dc22-1420 |
0.326 |
|
| 2022 |
Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. The New England Journal of Medicine. 387: 1075-1088. PMID 36129997 DOI: 10.1056/NEJMoa2200436 |
0.407 |
|
| 2022 |
Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. The New England Journal of Medicine. 387: 1063-1074. PMID 36129996 DOI: 10.1056/NEJMoa2200433 |
0.415 |
|
| 2022 |
Braffett BH, Bebu I, El Ghormli L, Cowie CC, Sivitz WI, Pop-Busui R, Larkin ME, Gubitosi-Klug RA, Nathan DM, Lachin JM, Dagogo-Jack S. Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes. Jama Network Open. 5: e2230710. PMID 36074461 DOI: 10.1001/jamanetworkopen.2022.30710 |
0.66 |
|
| 2022 |
Lachin JM, Bebu I, Gao X, Nathan DM, Zinman B. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care. PMID 35972222 DOI: 10.2337/dc21-2298 |
0.315 |
|
| 2022 |
Martin CL, Trapani VR, Backlund JC, Lee P, Braffett BH, Bebu I, Lachin JM, Jacobson AM, Gubitosi-Klug R, Herman WH. Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 45: 2037-2045. PMID 35880807 DOI: 10.2337/dc21-2119 |
0.698 |
|
| 2022 |
Jacobson AM, Braffett BH, Erus G, Ryan CM, Biessels GJ, Luchsinger JA, Bebu I, Gubitosi-Klug RA, Desiderio L, Lorenzi GM, Trapani VR, Lachin JM, Bryan RN, Habes M, Nasrallah IM. Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. Diabetes Care. PMID 35699949 DOI: 10.2337/dc21-2438 |
0.664 |
|
| 2022 |
Schwartz AV, Backlund JC, de Boer IH, Rubin MR, Barnie A, Farrell K, Trapani VR, Gregory NS, Wallia A, Bebu I, Lachin JM, Braffett BH, Gubitosi-Klug R. Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. The Lancet. Diabetes & Endocrinology. PMID 35576955 DOI: 10.1016/S2213-8587(22)00103-6 |
0.672 |
|
| 2022 |
Turkbey EB, Backlund JC, Gai N, Nacif M, van der Geest RJ, Lachin JM, Armstrong A, Volpe GJ, Nazarian S, Lima JAC, Bluemke DA. Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. The American Journal of Cardiology. PMID 35501170 DOI: 10.1016/j.amjcard.2022.03.036 |
0.373 |
|
| 2022 |
Rubin MR, de Boer IH, Backlund JC, Arends V, Gubitosi-Klug R, Wallia A, Sinha Gregory N, Barnie A, Burghardt AJ, Lachin JM, Braffett BH, Schwartz AV. Biochemical Markers of Bone Turnover in Older Adults with Type 1 Diabetes. The Journal of Clinical Endocrinology and Metabolism. PMID 35188961 DOI: 10.1210/clinem/dgac099 |
0.699 |
|
| 2022 |
Gubitosi-Klug RA, Braffett BH, Bebu I, Johnson ML, Farrell K, Kenny D, Trapani VR, Meadema-Mayer L, Soliman EZ, Pop-Busui R, Lachin JM, Bergenstal RM, Tamborlane WV. Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care. PMID 35076697 DOI: 10.2337/dc21-0629 |
0.712 |
|
| 2022 |
Monnier VM, Sell DR, Gao X, Genuth SM, Lachin JM, Bebu I. Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. Bmj Open Diabetes Research & Care. 10. PMID 35058313 DOI: 10.1136/bmjdrc-2021-002667 |
0.32 |
|
| 2022 |
Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM. Erratum. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261. Diabetes Care. PMID 35020815 DOI: 10.2337/dc22-er03a |
0.415 |
|
| 2022 |
Perkins BA, Bebu I, Gao X, Karger AB, Hirsch IB, Karanchi H, Molitch ME, Zinman B, Lachin JM, de Boer IH. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care. PMID 35015817 DOI: 10.2337/dc21-1883 |
0.354 |
|
| 2021 |
Polak JF, Backlund JC, Budoff M, Raskin P, Bebu I, Lachin JM. Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. Journal of the American Heart Association. 10: e022922. PMID 34873921 DOI: 10.1161/JAHA.121.022922 |
0.321 |
|
| 2021 |
Nathan DM, Krause-Steinrauf H, Braffett BH, Arends VL, Younes N, McGee P, Lund C, Johnson M, Lorenzi G, Gao X, Steffes MW, Lachin JM. Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. Plos One. 16: e0257154. PMID 34780485 DOI: 10.1371/journal.pone.0257154 |
0.619 |
|
| 2021 |
Lachin JM, Nathan DM. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care. PMID 34548284 DOI: 10.2337/dc20-3097 |
0.37 |
|
| 2021 |
Utzschneider KM, Younes N, Rasouli N, Barzilay JI, Banerji MA, Cohen RM, Gonzalez EV, Ismail-Beigi F, Mather KJ, Raskin P, Wexler DJ, Lachin JM, Kahn SE. Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. Bmj Open Diabetes Research & Care. 9. PMID 34531242 DOI: 10.1136/bmjdrc-2021-002264 |
0.402 |
|
| 2021 |
Lachin JM, Bebu I, Nathan DM. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care. PMID 34380706 DOI: 10.2337/dc21-1331 |
0.462 |
|
| 2021 |
Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ. The Utility of Using ECG Measures of Heart Rate Variability as a Measure of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes. Journal of Diabetes Investigation. PMID 34309223 DOI: 10.1111/jdi.13635 |
0.608 |
|
| 2021 |
Jenkins AJ, Braffett BH, Basu A, Bebu I, Dagogo-Jack S, Orchard TJ, Wallia A, Lopes-Virella MF, Garvey WT, Lachin JM, Lyons TJ. Serum urate and cardiovascular events in the DCCT/EDIC study. Scientific Reports. 11: 14182. PMID 34244538 DOI: 10.1038/s41598-021-90785-4 |
0.668 |
|
| 2021 |
Jacobson AM, Ryan CM, Braffett BH, Gubitosi-Klug RA, Lorenzi GM, Luchsinger JA, Trapani VR, Bebu I, Chaytor N, Hitt SM, Farrell K, Lachin JM. Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. The Lancet. Diabetes & Endocrinology. PMID 34051936 DOI: 10.1016/S2213-8587(21)00086-3 |
0.678 |
|
| 2021 |
Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, Miller R, Palmer J, Tamborlane W, Wallia A, Kosiborod M, Lachin JM, Bebu I. Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care. PMID 33980605 DOI: 10.2337/dc20-3104 |
0.509 |
|
| 2021 |
Bebu I, Keshavarzi S, Gao X, Braffett BH, Canty AJ, Herman WH, Orchard TJ, Dagogo-Jack S, Nathan DM, Lachin JM, Paterson AD. Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. PMID 33883194 DOI: 10.2337/dc20-2388 |
0.708 |
|
| 2021 |
Utzschneider KM, Younes N, Rasouli N, Barzilay J, Banerji MA, Cohen RM, Gonzalez EV, Mather KJ, Ismail-Beigi F, Raskin P, Wexler DJ, Lachin JM, Kahn SE. Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications. 107912. PMID 33752962 DOI: 10.1016/j.jdiacomp.2021.107912 |
0.328 |
|
| 2021 |
Gubitosi-Klug RA, Braffett BH, Hitt S, Arends V, Uschner D, Jones K, Diminick L, Karger AB, Paterson AD, Roshandel D, Marcovina S, Lachin JM, Steffes M, Palmer JP. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. The Journal of Clinical Investigation. 131. PMID 33529168 DOI: 10.1172/JCI143011 |
0.659 |
|
| 2020 |
Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Nathan DM, Herman WH, Lachin JM. Moderation of the Effect of Glycemia on the Risk of Cardiovascular Disease in Type 1 Diabetes: the DCCT/EDIC Study. Diabetes Research and Clinical Practice. 108591. PMID 33310124 DOI: 10.1016/j.diabres.2020.108591 |
0.728 |
|
| 2020 |
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV. Erratum. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017;40:1010-1016. Diabetes Care. PMID 33158952 DOI: 10.2337/dc21-er01a |
0.714 |
|
| 2020 |
Hainsworth DP, Gao X, Bebu I, Das A, Olmos de Koo L, Barkmeier AJ, Tamborlane W, Lachin JM, Aiello LP. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: the DCCT/EDIC Study. Ophthalmology. PMID 32941962 DOI: 10.1016/J.Ophtha.2020.09.014 |
0.485 |
|
| 2020 |
Bebu I, Braffett BH, Lachin JM. The minimum intensity of a mixed exposure that increases the risk of an outcome. Statistics in Medicine. PMID 32882751 DOI: 10.1002/Sim.8705 |
0.582 |
|
| 2020 |
Jaffa MA, Bebu I, Luttrell D, Braffett BH, Lachin JM, Hunt K, Lopes-Virella M, Luttrell L, Lyons TJ, Jaffa AA. Longitudinal Plasma Kallikrein Levels and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. PMID 32826295 DOI: 10.2337/Db20-0427 |
0.645 |
|
| 2020 |
Bebu I, Braffett BH, Schade D, Sivitz W, Malone JI, Pop-Busui R, Lorenzi GM, Lee P, Trapani VR, Wallia A, Herman WH, Lachin JM. An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care. PMID 32788280 DOI: 10.2337/Dc20-0226 |
0.753 |
|
| 2020 |
Chen Z, Miao F, Braffett BH, Lachin JM, Zhang L, Wu X, Roshandel D, Carless M, Li XA, Tompkins JD, Kaddis JS, Riggs AD, Paterson AD, Natarajan R. DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. Nature Metabolism. PMID 32694834 DOI: 10.1038/s42255-020-0231-8 |
0.676 |
|
| 2020 |
Lachin JM, Nathan DM, Zinman B, Bebu I. Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291-299. Diabetes. 69: e7-e8. PMID 32561623 DOI: 10.2337/Db20-0311 |
0.394 |
|
| 2020 |
Lachin JM, Bebu I, Braffett B. Models to Assess the Association of a Semi-Quantitative Exposure With Outcomes. American Journal of Epidemiology. PMID 32556076 DOI: 10.1093/Aje/Kwaa071 |
0.643 |
|
| 2020 |
Braffett BH, Gubitosi-Klug RA, Albers JW, Feldman EL, Martin CL, White NH, Orchard TJ, Lopes-Virella M, Lachin JM, Pop-Busui R. Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. PMID 32051148 DOI: 10.2337/Db19-1046 |
0.734 |
|
| 2020 |
Bebu I, Schade D, Braffett B, Kosiborod M, Lopes-Virella M, Soliman EZ, Herman WH, Bluemke DA, Wallia A, Orchard T, Lachin JM. Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. PMID 32001614 DOI: 10.2337/Dc19-2292 |
0.75 |
|
| 2020 |
Jacobson AM, Ryan CM, Braffett BH, Gubitosi-Klug R, Lorenzi GM, Luchsinger JA, Trapani VR, Bebu I, Chaytor N, Hitt SM, Farrell K, Lachin JM. 286-OR: Biomedical Predictors of Cognitive Decline in Older Participants with T1DM: Longitudinal Follow-Up of the DCCT/EDIC Cohort Diabetes. 69. DOI: 10.2337/Db20-286-Or |
0.631 |
|
| 2020 |
Schwartz AV, Backlund JC, Deboer I, Rubin M, Barnie AR, Farrell K, Trapani VR, Gregory NS, Wallia A, Lachin JM, Braffett BH, Gubitosi-Klug R, Dcct. 187-LB: Risk Factors for Lower Hip-Bone Density in Older Adults with Type 1 Diabetes Diabetes. 69. DOI: 10.2337/Db20-187-Lb |
0.681 |
|
| 2019 |
Riddle MC, Blonde L, Gerstein HC, Gregg EW, Holman RR, Lachin JM, Nichols GA, Turchin A, Cefalu WT. Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care. 42: 1136-1146. PMID 31666233 DOI: 10.2337/Dci19-0020 |
0.447 |
|
| 2019 |
Braffett BH, Lorenzi GM, Cowie CC, Gao X, Bainbridge KE, Cruickshanks KJ, Kramer JR, Gubitosi-Klug RA, Larkin ME, Barnie A, Lachin JM, Schade DS. RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. PMID 31412233 DOI: 10.4158/Ep-2019-0193 |
0.696 |
|
| 2019 |
Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM. Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664. Diabetes Care. 42: e137. PMID 31332032 DOI: 10.2337/Dci19-0026 |
0.671 |
|
| 2019 |
Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Gao X, Lachin JM. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. PMID 31217176 DOI: 10.2337/Db19-0358 |
0.67 |
|
| 2019 |
Gubitosi-Klug RA, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV. Screening eye exams in youth with type 1 diabetes under 18 years of age: once may be enough? Pediatric Diabetes. PMID 31206973 DOI: 10.1111/Pedi.12877 |
0.545 |
|
| 2019 |
Molitch ME, Gao X, Bebu I, de Boer IH, Lachin J, Paterson A, Perkins B, Saenger AK, Steffes M, Zinman B. Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 31123181 DOI: 10.2215/Cjn.14831218 |
0.571 |
|
| 2019 |
Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM. Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. PMID 30894365 DOI: 10.2337/Dc18-1613 |
0.753 |
|
| 2019 |
Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, Strowig S, Raskin P, Lachin JM. The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials. Jacc. Cardiovascular Imaging. PMID 30878435 DOI: 10.1016/J.Jcmg.2019.01.014 |
0.503 |
|
| 2019 |
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care. PMID 30833370 DOI: 10.2337/Dc18-2062 |
0.514 |
|
| 2019 |
Hainsworth DP, Bebu I, Aiello LP, Sivitz W, Gubitosi-Klug R, Malone J, White NH, Danis R, Wallia A, Gao X, Barkmeier AJ, Das A, Patel S, Gardner TW, Lachin JM, et al. Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. PMID 30833368 DOI: 10.2337/Dc18-2308 |
0.584 |
|
| 2019 |
Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. PMID 30728218 DOI: 10.2337/Dc18-1574 |
0.735 |
|
| 2019 |
Braffett BH, Rice MM, Young HA, Lachin JM. Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. Plos One. 14: e0210367. PMID 30615671 DOI: 10.1371/Journal.Pone.0210367 |
0.679 |
|
| 2019 |
Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Lachin J, Dcct. 445-P: Modified LDL-Immune Complexes (IC) and the Risk of CVD in Type 1 Diabetes Diabetes. 68. DOI: 10.2337/Db19-445-P |
0.659 |
|
| 2019 |
Sell D, Lachin J, Bebu I, Monnier VM. 1541-P: Association between Urine Free Advanced Glycation End Products (AGEs) at Three Time Points during the DCCT/EDIC and Subsequent Risk of Microvascular Complications in Type 1 Diabetes Diabetes. 68. DOI: 10.2337/Db19-1541-P |
0.497 |
|
| 2019 |
Monnier VM, Sell D, Lachin J, Bebu I. 1540-P: Plasma Advanced Glycation End Products (AGEs) at Three Time Points during the DCCT/EDIC Are Associated with Subsequent Risk of Microvascular Complications in Type 1 Diabetes Diabetes. 68. DOI: 10.2337/Db19-1540-P |
0.484 |
|
| 2019 |
Molitch M, Gao X, Bebu I, De Boer I, Lachin J, Paterson A, Perkins B, Saenger A, Steffes M, Zinman B. OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Or14-4 |
0.456 |
|
| 2018 |
Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 138: 1599-1601. PMID 30354516 DOI: 10.1161/Circulationaha.118.033810 |
0.495 |
|
| 2018 |
Schade DS, Lorenzi GM, Braffett BH, Gao X, Bainbridge KE, Barnie A, Cruickshanks KJ, Dalton D, Diminick L, Gubitosi-Klug R, Kramer JR, Lachin JM, Larkin ME, Cowie CC. Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Diabetes Care. PMID 30254082 DOI: 10.2337/Dc18-0625 |
0.745 |
|
| 2018 |
Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, Prosser LA, Lachin JM. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? Journal of Diabetes and Its Complications. PMID 30082172 DOI: 10.1016/J.Jdiacomp.2018.05.007 |
0.701 |
|
| 2018 |
Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, Prosser LA, Lachin JM. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). Journal of Diabetes and Its Complications. PMID 30064713 DOI: 10.1016/J.Jdiacomp.2018.06.005 |
0.726 |
|
| 2018 |
Home P, Lachin J. Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655-662. Diabetes Care. 41: e64. PMID 29559462 DOI: 10.2337/Dc17-2405 |
0.434 |
|
| 2018 |
Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Journal of the American College of Cardiology. 71: 364-367. PMID 29348030 DOI: 10.1016/J.Jacc.2017.11.022 |
0.516 |
|
| 2018 |
Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care. PMID 29311155 DOI: 10.2337/Dc17-1778 |
0.483 |
|
| 2018 |
BEISSWENGER PJ, BEBU I, HOWELL S, LACHIN J. Advanced Glycation End Products (AGEs)-Role in Development and Progression of Kidney Disease in Type 1 Diabetes in DCCT/EDIC Diabetes. 67: 521-P. DOI: 10.2337/Db18-521-P |
0.445 |
|
| 2018 |
Basu A, Braffett B, Jenkins A, Bebu I, Klein RL, Lopes-Virella MF, Dagogo-Jack S, Orchard TJ, Wallia A, Lachin J, Garvey WT, Lyons T, Dcct. Uric Acid and Cardiovascular Disease in Type 1 Diabetes Diabetes. 67. DOI: 10.2337/Db18-189-Lb |
0.68 |
|
| 2018 |
Rasouli N, Cohen RM, Defronzo RA, Inzucchi S, Ismail-Beigi F, Kahn SE, Utzschneider K, Lachin J, Younes N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort Diabetes. 67. DOI: 10.2337/Db18-1822-P |
0.329 |
|
| 2018 |
GUBITOSI-KLUG R, BRAFFETT B, HITT SM, ARENDS V, STEFFES M, SAENGER AK, LACHIN J, PALMER JP. Residual Beta-Cell Function in Long Duration Type 1 Diabetes (T1D) Diabetes. 67: 1686-P. DOI: 10.2337/Db18-1686-P |
0.621 |
|
| 2018 |
Tang WHW, McGee P, Lachin JM, Li DY, Hoogwerf B, Hazen SL, Dcct. Oxidative stress and cardiovascular risk in type 1 diabetes mellitus: Insights from the DCCT/EDIC study Journal of the American Heart Association. 7. DOI: 10.1161/Jaha.117.008368 |
0.484 |
|
| 2017 |
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. PMID 29203583 DOI: 10.2337/Dc17-1096 |
0.438 |
|
| 2017 |
de Boer IH, Gao X, Bebu I, Hoofnagle AN, Lachin JM, Paterson A, Perkins BA, Saenger AK, Steffes MW, Zinman B, Molitch ME. Biomarkers of tubulointerstitial damage and function in type 1 diabetes. Bmj Open Diabetes Research & Care. 5: e000461. PMID 29177052 DOI: 10.1136/Bmjdrc-2017-000461 |
0.508 |
|
| 2017 |
Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM. Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777-783. Diabetes Care. 40: e165-e166. PMID 29061594 DOI: 10.2337/Dci17-0038 |
0.502 |
|
| 2017 |
Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. European Heart Journal. PMID 29020355 DOI: 10.1093/Eurheartj/Ehx511 |
0.36 |
|
| 2017 |
Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, et al. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. PMID 28986504 DOI: 10.2337/Dc17-1091 |
0.522 |
|
| 2017 |
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George JT, Woerle HJ, Broedl UC, von Eynatten M, Zinman B. Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease. Circulation. PMID 28904068 DOI: 10.1161/Circulationaha.117.028268 |
0.449 |
|
| 2017 |
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED. Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. Hypertension (Dallas, Tex. : 1979). PMID 28847886 DOI: 10.1161/Hypertensionaha.117.09482 |
0.489 |
|
| 2017 |
Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, Nathan DM, Lachin JM. The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia. PMID 28711972 DOI: 10.1007/S00125-017-4374-4 |
0.7 |
|
| 2017 |
Nathan DM, Bebu I, Lachin JM. Frequency of Evidence-Based Screening for Diabetic Retinopathy. The New England Journal of Medicine. 377: 195. PMID 28700836 DOI: 10.1056/Nejmc1706322 |
0.445 |
|
| 2017 |
Sacks DB, Bebu I, Lachin JM. Refining Measurement of Hemoglobin A1c. Clinical Chemistry. PMID 28634223 DOI: 10.1373/Clinchem.2016.268573 |
0.356 |
|
| 2017 |
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV. The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. PMID 28550194 DOI: 10.2337/Dc16-2723 |
0.733 |
|
| 2017 |
Bebu I, Lachin JM. Optimal screening schedules for disease progression with application to diabetic retinopathy. Biostatistics (Oxford, England). PMID 28430872 DOI: 10.1093/Biostatistics/Kxx009 |
0.503 |
|
| 2017 |
Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. The New England Journal of Medicine. 376: 1507-1516. PMID 28423305 DOI: 10.1056/Nejmoa1612836 |
0.541 |
|
| 2017 |
Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care. PMID 28404658 DOI: 10.2337/Dc16-2426 |
0.58 |
|
| 2017 |
Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. PMID 28386035 DOI: 10.1161/Strokeaha.116.015756 |
0.509 |
|
| 2017 |
Guglielmi C, Del Toro R, Lauria A, Maurizi AR, Fallucca S, Cappelli A, Angeletti S, Lachin JM, Pozzilli P. Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes. Diabetes/Metabolism Research and Reviews. 33. PMID 28371189 DOI: 10.1002/Dmrr.2899 |
0.341 |
|
| 2017 |
Soliman EZ, Backlund JC, Bebu I, Orchard TJ, Zinman B, Lachin JM. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. PMID 28302651 DOI: 10.2337/Dc16-2050 |
0.555 |
|
| 2016 |
Armstrong AC, Ambale-Venkatesh B, Turkbey E, Donekal S, Chamera E, Backlund JY, Cleary P, Lachin J, Bluemke DA, Lima JA. Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. PMID 27986796 DOI: 10.2337/Dc16-1889 |
0.554 |
|
| 2016 |
de Boer IH, Gao X, Cleary PA, Bebu I, Lachin JM, Molitch ME, Orchard T, Paterson AD, Perkins BA, Steffes MW, Zinman B. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 27797889 DOI: 10.2215/Cjn.02870316 |
0.551 |
|
| 2016 |
Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR, et al. Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care. PMID 27630212 DOI: 10.2337/Dc15-2780 |
0.393 |
|
| 2016 |
Orchard TJ, Backlund JC, Costacou T, Cleary P, Lopes-Virella M, Levy AP, Lachin JM. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Journal of Diabetes and Its Complications. PMID 27539884 DOI: 10.1016/J.Jdiacomp.2016.07.014 |
0.563 |
|
| 2016 |
Darabian S, Backlund JY, Cleary PA, Sheidaee N, Bebu I, Lachin JM, Budoff MJ. Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. Plos One. 11: e0159958. PMID 27459689 DOI: 10.1371/Journal.Pone.0159958 |
0.448 |
|
| 2016 |
McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. Jama Cardiology. 1: 126-35. PMID 27437883 DOI: 10.1001/Jamacardio.2016.0103 |
0.475 |
|
| 2016 |
Braffett BH, Bebu I, Lachin JM, Dagogo-Jack S, Larkin M, Sivitz W, Kolterman O, Genuth S. Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study Diabetes Care. 39: 1621-1630. PMID 27436274 DOI: 10.2337/Dc16-0502 |
0.732 |
|
| 2016 |
Lachin JM, Bebu I, Cleary PA, Control D, Trial C. Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes Care. 39: 1378. PMID 27411699 DOI: 10.2337/Dc15-2399 |
0.469 |
|
| 2016 |
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine. PMID 27299675 DOI: 10.1056/Nejmoa1515920 |
0.488 |
|
| 2016 |
Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proceedings of the National Academy of Sciences of the United States of America. PMID 27162351 DOI: 10.1073/Pnas.1603712113 |
0.669 |
|
| 2016 |
Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 374: 1094. PMID 26981940 DOI: 10.1056/NEJMc1600827 |
0.392 |
|
| 2016 |
Soliman EZ, Backlund JY, Bebu I, Li Y, Zhang ZM, Cleary PA, Lachin JM. Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Journal of the American Heart Association. 5. PMID 26976878 DOI: 10.1161/Jaha.115.002882 |
0.553 |
|
| 2016 |
Nathan DM, Bebu I, Braffett BH, Orchard TJ, Cowie CC, Lopes-Virella M, Schutta M, Lachin JM. Risk factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes. PMID 26895792 DOI: 10.2337/Db15-1517 |
0.704 |
|
| 2016 |
Sell DR, Sun W, Gao X, Strauch C, Lachin JM, Cleary PA, Genuth S, Monnier VM. Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. Cardiovascular Diabetology. 15: 30. PMID 26864236 DOI: 10.1186/S12933-016-0343-3 |
0.558 |
|
| 2016 |
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. European Heart Journal. PMID 26819227 DOI: 10.1093/Eurheartj/Ehv728 |
0.405 |
|
| 2016 |
Gubitosi-Klug RA, Lachin JM, Backlund JYC, Lorenzi GM, Brillon DJ, Orchard TJ. Intensive diabetes treatment and cardiovascular outcomes in type1 diabetes: The DCCT/EDIC study 30-year follow-up Diabetes Care. 39: 686-693. DOI: 10.2337/Dc15-1990 |
0.558 |
|
| 2016 |
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk Canadian Journal of Diabetes. 40: S4-S5. DOI: 10.1016/j.jcjd.2016.08.013 |
0.366 |
|
| 2016 |
Fitchett DH, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen OE, Woerle H, Broedl UC, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK Journal of the American College of Cardiology. 67: 1869. DOI: 10.1016/J.Cjca.2016.07.182 |
0.47 |
|
| 2016 |
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK Canadian Journal of Cardiology. 32: S122-S123. DOI: 10.1016/j.cjca.2016.07.182 |
0.366 |
|
| 2015 |
Nathan DM, Genuth SM, Zinman B, Lachin JM. Data sharing is desirable, but benefits should not be exaggerated. Bmj (Clinical Research Ed.). 351: h5508. PMID 26489751 DOI: 10.1136/Bmj.H5508 |
0.534 |
|
| 2015 |
Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S. Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovascular Diabetology. 14: 138. PMID 26453359 DOI: 10.1186/s12933-015-0295-z |
0.598 |
|
| 2015 |
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 373: 2117-28. PMID 26378978 DOI: 10.1056/Nejmoa1504720 |
0.495 |
|
| 2015 |
Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovascular Diabetology. 14: 118. PMID 26341632 DOI: 10.1186/S12933-015-0266-4 |
0.597 |
|
| 2015 |
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. PMID 26052984 DOI: 10.1056/Nejmoa1501352 |
0.515 |
|
| 2015 |
Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM. Intensive diabetes therapy and ocular surgery in type 1 diabetes. The New England Journal of Medicine. 372: 1722-33. PMID 25923552 DOI: 10.1056/Nejmoa1409463 |
0.706 |
|
| 2015 |
Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diabetes & Vascular Disease Research. 12: 164-74. PMID 25780262 DOI: 10.1177/1479164115570301 |
0.556 |
|
| 2015 |
Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. Jama. 313: 45-53. PMID 25562265 DOI: 10.1001/Jama.2014.16107 |
0.514 |
|
| 2015 |
Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. Journal of Diabetes and Its Complications. 29: 108-14. PMID 25441222 DOI: 10.1016/J.Jdiacomp.2014.08.004 |
0.514 |
|
| 2015 |
Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi CA, Crandall J, Florez JC, Fowler S, Goldberg R, Kahn SE, Knowler WC, Lachin JM, Murphy MB, Venditti E. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes. 64: 989-98. PMID 25277389 DOI: 10.2337/Db14-0333 |
0.506 |
|
| 2015 |
Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 64: 631-42. PMID 25204977 DOI: 10.2337/Db14-0930 |
0.705 |
|
| 2015 |
Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, Monnier VM. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes. 64: 266-78. PMID 25187362 DOI: 10.2337/Db14-0215 |
0.665 |
|
| 2015 |
Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes Cardiovascular Diabetology. 14. DOI: 10.1186/s12933-015-0266-4 |
0.598 |
|
| 2014 |
Ma Y, Lai Y, Lachin JM. Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression. Plos One. 9: e113948. PMID 25473827 DOI: 10.1371/Journal.Pone.0113948 |
0.353 |
|
| 2014 |
Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovascular Diabetology. 13: 102. PMID 24943000 DOI: 10.1186/1475-2840-13-102 |
0.45 |
|
| 2014 |
de Boer IH, Afkarian M, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology : Jasn. 25: 2342-50. PMID 24925722 DOI: 10.1681/Asn.2013091004 |
0.684 |
|
| 2014 |
McGee P, Steffes M, Nowicki M, Bayless M, Gubitosi-Klug R, Cleary P, Lachin J, Palmer J. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine : a Journal of the British Diabetic Association. 31: 1264-8. PMID 24836354 DOI: 10.1111/Dme.12504 |
0.551 |
|
| 2014 |
Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R, et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 63: 1748-62. PMID 24458354 DOI: 10.2337/Db13-1251 |
0.651 |
|
| 2014 |
Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 37: 39-43. PMID 24356596 DOI: 10.2337/Dc13-2116 |
0.526 |
|
| 2014 |
de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Zinman B, Steffes MW. Longitudinal changes in estimated and measured GFR in type 1 diabetes. Journal of the American Society of Nephrology : Jasn. 25: 810-8. PMID 24309189 DOI: 10.1681/Asn.2013050557 |
0.596 |
|
| 2014 |
Sun W, Larsen MD, Lachin JM. Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. Statistics in Medicine. 33: 1288-306. PMID 24258796 DOI: 10.1002/Sim.6037 |
0.603 |
|
| 2014 |
Lachin JM, McGee P, Palmer JP. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 63: 739-48. PMID 24089509 DOI: 10.2337/Db13-0881 |
0.374 |
|
| 2014 |
Nathan DM, McGee P, Steffes MW, Lachin JM. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 63: 282-90. PMID 23990364 DOI: 10.2337/Db13-0782 |
0.43 |
|
| 2014 |
Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Kempthorne-Rawson J, Newman J, Johansen O, Woerle H, Broedl U. Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes Diabetologie Und Stoffwechsel. 9. DOI: 10.1055/s-0034-1374995 |
0.421 |
|
| 2014 |
de Boer I, Sun W, Gao X, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study The Lancet Diabetes and Endocrinology. 2: 793-800. DOI: 10.1016/S2213-8587(14)70155-X |
0.71 |
|
| 2013 |
Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 62: 3976-86. PMID 24264395 DOI: 10.2337/Db13-1093 |
0.555 |
|
| 2013 |
Grassi MA, Sun W, Gangaputra S, Cleary PA, Hubbard L, Lachin JM, Gao X, Kiss S, Barkmeier AJ, Almony A, Davis M, Klein R, Danis RP. Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. Ophthalmology. 120: 2580-6. PMID 23890420 DOI: 10.1016/J.Ophtha.2013.06.002 |
0.655 |
|
| 2013 |
Orchard TJ, Sun W, Cleary PA, Genuth SM, Lachin JM, McGee P, Paterson AD, Raskin P, Anbinder Y, Levy AP. Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes. 62: 3218-23. PMID 23761102 DOI: 10.2337/Db13-0256 |
0.682 |
|
| 2013 |
Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 36: 2254-61. PMID 23690531 DOI: 10.2337/Dc13-0356 |
0.502 |
|
| 2013 |
Sachs MC, Brunzell JD, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, Steffes MW, Zinman B, de Boer IH. Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. Diabetes Care. 36: 2423-9. PMID 23530012 DOI: 10.2337/Dc12-2020 |
0.393 |
|
| 2013 |
Genuth SM, Backlund JY, Bayless M, Bluemke DA, Cleary PA, Crandall J, Lachin JM, Lima JA, Miao C, Turkbey EB. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes. 62: 3561-9. PMID 23520132 DOI: 10.2337/Db12-0546 |
0.479 |
|
| 2013 |
Turkbey EB, Redheuil A, Backlund JY, Small AC, Cleary PA, Lachin JM, Lima JA, Bluemke DA. Aortic distensibility in type 1 diabetes. Diabetes Care. 36: 2380-7. PMID 23474588 DOI: 10.2337/Dc12-0393 |
0.569 |
|
| 2013 |
Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes & Vascular Disease Research. 10: 289-301. PMID 23449634 DOI: 10.1177/1479164112475102 |
0.434 |
|
| 2013 |
Purnell JQ, John EH, Cleary PA, Nathan DM, Lachin JM, Zinman B, Brunzell JD. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study Circulation. 127: 180-187. PMID 23212717 DOI: 10.1161/CIRCULATIONAHA.111.077487 |
0.487 |
|
| 2013 |
Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, Genuth S. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. Journal of Diabetes and Its Complications. 27: 141-9. PMID 23153673 DOI: 10.1016/J.Jdiacomp.2012.10.004 |
0.653 |
|
| 2013 |
Zinman B, Inzucchi SE, Lachin J, Wanner C, Ferrari R, Bluhmki E, Hantel S, Johansen OE, Woerle H, Broedl UC. Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D) Canadian Journal of Diabetes. 37: S29-S30. DOI: 10.1016/J.Jcjd.2013.08.088 |
0.507 |
|
| 2012 |
de Boer IH, Sachs MC, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. The Journal of Clinical Endocrinology and Metabolism. 97: 4780-8. PMID 22990096 DOI: 10.1210/Jc.2012-2852 |
0.639 |
|
| 2012 |
Chahal H, Backlund JY, Cleary PA, Lachin JM, Polak JF, Lima JA, Bluemke DA. Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). The American Journal of Cardiology. 110: 1534-40. PMID 22884107 DOI: 10.1016/J.Amjcard.2012.07.014 |
0.499 |
|
| 2012 |
Hotaling JM, Waggott DR, Goldberg J, Jarvik G, Paterson AD, Cleary PA, Lachin J, Sarma A, Wessells H. Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. The Journal of Urology. 188: 514-20. PMID 22704111 DOI: 10.1016/J.Juro.2012.04.001 |
0.472 |
|
| 2012 |
Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 61: 2066-73. PMID 22688329 DOI: 10.1089/Dia.2013.1510 |
0.384 |
|
| 2012 |
Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 27: 1416-23. PMID 21856760 DOI: 10.1093/Ndt/Gfr454 |
0.353 |
|
| 2011 |
Lachin JM, McGee PL, Greenbaum CJ, Palmer J, Pescovitz MD, Gottlieb P, Skyler J. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. Plos One. 6: e26471. PMID 22102862 DOI: 10.1371/Journal.Pone.0026471 |
0.442 |
|
| 2011 |
de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. The New England Journal of Medicine. 365: 2366-76. PMID 22077236 DOI: 10.1056/Nejmoa1111732 |
0.694 |
|
| 2011 |
Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, Liu CY, Lima JA, Bluemke DA. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 124: 1737-46. PMID 21947298 DOI: 10.1161/Circulationaha.111.022327 |
0.49 |
|
| 2011 |
Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A. Effect of rituximab on human in vivo antibody immune responses. The Journal of Allergy and Clinical Immunology. 128: 1295-1302.e5. PMID 21908031 DOI: 10.1016/J.Jaci.2011.08.008 |
0.396 |
|
| 2011 |
Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 187: 1998-2005. PMID 21775681 DOI: 10.4049/Jimmunol.1100539 |
0.445 |
|
| 2011 |
Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology : Cjasn. 6: 1032-40. PMID 21454723 DOI: 10.2215/Cjn.09291010 |
0.488 |
|
| 2011 |
Wessells H, Penson DF, Cleary P, Rutledge BN, Lachin JM, McVary KT, Schade DS, Sarma AV. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. The Journal of Urology. 185: 1828-34. PMID 21420129 DOI: 10.1016/J.Juro.2010.12.098 |
0.581 |
|
| 2011 |
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 60: 1552-60. PMID 21415383 DOI: 10.2337/Db10-1392 |
0.455 |
|
| 2011 |
de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine. 171: 412-20. PMID 21403038 DOI: 10.1001/Archinternmed.2011.16 |
0.696 |
|
| 2011 |
Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, Nathan DM. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes. 60: 607-13. PMID 21270271 DOI: 10.2337/Db10-0296 |
0.536 |
|
| 2011 |
Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 214: 462-7. PMID 21156319 DOI: 10.1016/J.Atherosclerosis.2010.11.012 |
0.331 |
|
| 2011 |
Sacks DB, Nathan DM, Lachin JM. Gaps in the glycation gap hypothesis. Clinical Chemistry. 57: 150-2. PMID 21127149 DOI: 10.1373/Clinchem.2010.158071 |
0.477 |
|
| 2011 |
Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM. Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry. 57: 286-90. PMID 21030684 DOI: 10.1373/Clinchem.2010.150250 |
0.513 |
|
| 2011 |
Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 60: 582-9. PMID 20980456 DOI: 10.2337/Db10-0915 |
0.392 |
|
| 2011 |
Sosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS. A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes. 12: 85-90. PMID 20522170 DOI: 10.1111/J.1399-5448.2010.00662.X |
0.482 |
|
| 2010 |
Lachin JM. Point: Intensive glycemic control and mortality in ACCORD--a chance finding? Diabetes Care. 33: 2719-21. PMID 21115777 DOI: 10.2337/Dc10-1506 |
0.39 |
|
| 2010 |
Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Current Diabetes Reports. 10: 276-82. PMID 20464532 DOI: 10.1007/S11892-010-0120-8 |
0.559 |
|
| 2010 |
Younes N, Cleary PA, Steffes MW, de Boer IH, Molitch ME, Rutledge BN, Lachin JM, Dahms W. Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clinical Journal of the American Society of Nephrology : Cjasn. 5: 1235-42. PMID 20448066 DOI: 10.2215/Cjn.07901109 |
0.532 |
|
| 2010 |
Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 33: 1536-43. PMID 20413518 DOI: 10.2337/Dc09-1098 |
0.708 |
|
| 2010 |
Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 33: 1090-6. PMID 20150297 DOI: 10.2337/Dc09-1941 |
0.503 |
|
| 2010 |
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care. 33: 826-32. PMID 20067954 DOI: 10.2337/Dc09-1349 |
0.454 |
|
| 2010 |
Paterson AD, Waggott D, Boright AP, Hosseini SM, Shen E, Sylvestre MP, Wong I, Bharaj B, Cleary PA, Lachin JM, Below JE, Nicolae D, Cox NJ, Canty AJ, et al. A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes. 59: 539-49. PMID 19875614 DOI: 10.2337/Db09-0653 |
0.538 |
|
| 2010 |
Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 95: 134-42. PMID 19875477 DOI: 10.1210/Jc.2009-0572 |
0.358 |
|
| 2010 |
Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 33: 177-83. PMID 19808911 DOI: 10.2337/Dc09-1661 |
0.411 |
|
| 2010 |
Turkbey EB, Cleary PA, Backlund JY, Lachin JM, Nathan DM, Geest RJVD, Lima JA, Bluemke DA. Relationship of myocardial scar with cardiovascular disease risk factors in the diabetes control and complications trial (DCCT)/epidemiology of diabetes interventions and complications (EDIC) study Journal of Cardiovascular Magnetic Resonance. 12. DOI: 10.1186/1532-429X-12-S1-M6 |
0.512 |
|
| 2010 |
Hotaling J, Waggott D, Paterson A, Goldberg J, Lachin J, Cleary P, Wessells H. 703 GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL GENES FOR ERECTILE DYSFUNCTION RISK USING THE EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) DATABASE Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1144 |
0.456 |
|
| 2009 |
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, ... Lachin JM, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. The New England Journal of Medicine. 361: 2143-52. PMID 19940299 DOI: 10.1056/Nejmoa0904452 |
0.376 |
|
| 2009 |
Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 58: 2588-95. PMID 19675135 DOI: 10.2337/Db09-0249 |
0.412 |
|
| 2009 |
Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation. 119: 2886-93. PMID 19470886 DOI: 10.1161/Circulationaha.108.837369 |
0.502 |
|
| 2009 |
Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler DJ. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. The American Journal of Clinical Nutrition. 89: 518-24. PMID 19106241 DOI: 10.3945/Ajcn.2008.26498 |
0.476 |
|
| 2009 |
Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes. 10: 97-104. PMID 18823409 DOI: 10.1111/J.1399-5448.2008.00464.X |
0.553 |
|
| 2008 |
Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L. Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Annals of the New York Academy of Sciences. 1150: 14-24. PMID 19120262 DOI: 10.1196/Annals.1447.054 |
0.465 |
|
| 2008 |
White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM, Crofford O, Crandall J, Phillips M, Reid M, Brown-Friday J, Engel S, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial Archives of Ophthalmology. 126: 1707-1715. PMID 19064853 DOI: 10.1001/Archopht.126.12.1707 |
0.713 |
|
| 2008 |
de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, Lachin JM, Weiss NS, Brunzell JD. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Archives of Internal Medicine. 168: 1867-73. PMID 18809813 DOI: 10.1001/Archinternmed.2008.2 |
0.468 |
|
| 2008 |
Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 31: 1966-71. PMID 18628574 DOI: 10.2337/Dc07-2451 |
0.458 |
|
| 2008 |
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 31: 845-51. PMID 18223031 DOI: 10.2337/Dc07-2270 |
0.343 |
|
| 2008 |
Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes. 57: 995-1001. PMID 18223010 DOI: 10.2337/Db07-1618 |
0.483 |
|
| 2008 |
Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care. 31: 528-33. PMID 18000175 DOI: 10.2337/Dc07-1459 |
0.56 |
|
| 2008 |
Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes. 57: 218-28. PMID 17914031 DOI: 10.2337/Db07-1059 |
0.663 |
|
| 2008 |
Nathan DM, Genuth S, Rutledge B, Lachin J. Response to Comment on: Lachin et al. (2007) The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial: Diabetes 56:1913-1921, 2007 Diabetes. 57: e5-e5. DOI: 10.2337/Db07-1638 |
0.5 |
|
| 2007 |
Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 30: 2453-7. PMID 17536077 DOI: 10.2337/Dc06-2003 |
0.36 |
|
| 2007 |
Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care. 30: 2107-12. PMID 17468351 DOI: 10.2337/Dc06-1441 |
0.589 |
|
| 2007 |
Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 56: 1153-9. PMID 17395752 DOI: 10.2337/Db06-0918 |
0.503 |
|
| 2007 |
Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes. 56: 1913-21. PMID 17360979 DOI: 10.2337/Db07-0028 |
0.509 |
|
| 2006 |
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine. 355: 2427-43. PMID 17145742 DOI: 10.1056/Nejmoa066224 |
0.492 |
|
| 2006 |
Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, Nathan DM. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 55: 3556-65. PMID 17130504 DOI: 10.2337/Db06-0653 |
0.71 |
|
| 2006 |
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine : a Journal of the British Diabetic Association. 23: 1289-94. PMID 17116177 DOI: 10.1111/J.1464-5491.2006.02022.X |
0.526 |
|
| 2006 |
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 29: 2102-7. PMID 16936160 DOI: 10.2337/Dc06-0560 |
0.501 |
|
| 2006 |
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 55: 2357-64. PMID 16873701 DOI: 10.2337/Db06-0116 |
0.371 |
|
| 2006 |
Sparling YH, Younes N, Lachin JM, Bautista OM. Parametric survival models for interval-censored data with time-dependent covariates. Biostatistics (Oxford, England). 7: 599-614. PMID 16597670 DOI: 10.1093/Biostatistics/Kxj028 |
0.366 |
|
| 2006 |
Lachin JM, Cleary P, Crofford O, Genuth S, Nathan D, Clark C, Ferris F, Siebert C. Early termination of the Diabetes Control and Complications Trial Data Monitoring in Clinical Trials: a Case Studies Approach. 93-108. DOI: 10.1007/0-387-30107-0_9 |
0.397 |
|
| 2005 |
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine. 353: 2643-53. PMID 16371630 DOI: 10.1056/Nejmoa052187 |
0.543 |
|
| 2005 |
Genuth S, Lachin JM, Nathan DM. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. Diabetes Care. 28: 233; author reply 23. PMID 15616268 DOI: 10.2337/Diacare.28.1.233 |
0.447 |
|
| 2004 |
Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, Horton ES, Hoskin MA, Kriska A, Lachin J, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner JG, Venditti B, Wylie-Rosett J, et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research. 12: 1426-34. PMID 15483207 DOI: 10.1038/Oby.2004.179 |
0.483 |
|
| 2004 |
Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 53: 250-64. PMID 14693724 DOI: 10.2337/Diabetes.53.1.250 |
0.5 |
|
| 2004 |
Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. Erratum: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001 (Diabetes (2004) 53 (250-264)) Diabetes. 53. DOI: 10.2337/Diabetes.53.7.1934 |
0.5 |
|
| 2003 |
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. The New England Journal of Medicine. 348: 2294-303. PMID 12788993 DOI: 10.1056/Nejmoa022314 |
0.559 |
|
| 2003 |
Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 26: 36-47. PMID 12502656 DOI: 10.2337/Diacare.26.1.36 |
0.515 |
|
| 2003 |
Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F. Implications of the United kingdom prospective diabetes study. Diabetes Care. 26: S28-32. PMID 12502617 DOI: 10.2337/Diacare.26.2007.S28 |
0.531 |
|
| 2002 |
Haffner SM, Goldberg R, Ratner R, Lachin J, Temprosa M, Orchard T, Molitch M, Saad M. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance Hypertension. 40: 679-686. PMID 12411462 DOI: 10.1161/01.Hyp.0000035706.28494.09 |
0.632 |
|
| 2002 |
Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 25: 1737-43. PMID 12351470 DOI: 10.2337/Diacare.25.10.1737 |
0.533 |
|
| 2002 |
Skyler JS, Brown D, Chase HP, Collier E, Cowie C, Eisenbarth GS, Fradkin J, Grave G, Greenbaum C, Jackson RA, Kaufman FR, Krischer JP, Marks JB, Palmer JP, Ricker A, ... ... Lachin JM, et al. Effects of insulin in relatives of patients with type 1 diabetes mellitus New England Journal of Medicine. 346: 1685-1691. PMID 12037147 DOI: 10.1056/Nejmoa012350 |
0.515 |
|
| 2002 |
Genuth S, Lipps J, Lorenzi G, Nathan DM, Davis MD, Lachin JM, Cleary PA. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus Journal of the American Medical Association. 287: 2563-2569. PMID 12020338 |
0.411 |
|
| 2002 |
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 346: 393-403. PMID 11832527 DOI: 10.1056/Nejmoa012512 |
0.498 |
|
| 2001 |
Nathan DM, Davis M, Cleary P, Lachin J. Response to Cundy Diabetes Care. 24: 795-796. DOI: 10.2337/Diacare.24.4.795 |
0.38 |
|
| 2000 |
Lachin JM. Statistical considerations in the intent-to-treat principle Controlled Clinical Trials. 21: 167-189. PMID 10822117 DOI: 10.1016/S0197-2456(00)00046-5 |
0.315 |
|
| 2000 |
Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy New England Journal of Medicine. 342: 381-389. PMID 10666428 DOI: 10.1056/Nejm200002103420603 |
0.435 |
|
| 1999 |
Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 48: 870-80. PMID 10102706 DOI: 10.2337/Diabetes.48.4.870 |
0.522 |
|
| 1997 |
Cahill G.F. J, Buskirk ER, Delahanty LM, Fajans SS, Fleid JB, Holverson HE, Hoover JW, Horwitz RI, Hentz KI, Lachin JM, Lockwood DH, Service FJ, Thompson PD, Wheeler ML, Eachwege E, et al. Diet and exercise in noninsulin-dependent diabetes mellitus Nutrition. 13: 89-94. PMID 9106784 DOI: 10.1016/S0899-9007(97)00021-X |
0.336 |
|
| 1996 |
Nicolucci A, Hohman TC, Carinci F, Ferris F, Graepel JG, Lachin JM. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: A meta-analysis of individual patient data Diabetes Care. 19: 1091-1096. PMID 8886554 DOI: 10.2337/Diacare.19.10.1091 |
0.37 |
|
| 1996 |
Lachin JM. Distribution-free marginal analysis of repeated measures Drug Information Journal. 30: 1017-1028. DOI: 10.1177/009286159603000418 |
0.355 |
|
| 1995 |
Albers JW, Kenny DJ, Brown M, Greene D, Cleary PA, Lachin JM, Nathan DM. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial Annals of Neurology. 38: 869-880. PMID 8526459 |
0.429 |
|
| 1994 |
Townsend RR, Kapoor SC, Garber A, Gerard D, Nathan DM, Crofford OB, Lachin JM. The effect of intensive treatment of diabetes mellitus [2] New England Journal of Medicine. 330: 641-642. PMID 8302352 DOI: 10.1056/NEJM199403033300914 |
0.421 |
|
| 1994 |
Teuscher A, Reinli K, Nathan D, Crofford O, Genuth SM, Lachin J, Cleary P, Siebert C. Severe hypoglycaemia in Diabetes Control and Complications Trial The Lancet. 343: 1097-1098. PMID 7909111 DOI: 10.1016/S0140-6736(94)90206-2 |
0.521 |
|
| 1993 |
Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 329: 977-86. PMID 8366922 DOI: 10.1056/Nejm199309303291401 |
0.493 |
|
| 1992 |
Lachin JM, Lan SP. Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study Controlled Clinical Trials. 13: 62-79. PMID 1315665 DOI: 10.1016/0197-2456(92)90030-4 |
0.304 |
|
| 1988 |
Thall PF, Lachin JM. Analysis of recurrent events: Nonparametric methods for random-interval count data Journal of the American Statistical Association. 83: 339-347. DOI: 10.1080/01621459.1988.10478603 |
0.349 |
|
| 1987 |
Cahill GF, Buskirk ER, Delahanty LM, Fajans SS, Field JB, Holverson HE, Hoover JW, Horwitz RI, Hentz KI, Lachin JM, Lockwood DH, Service FJ, Thompson PD, Wheeler ML. Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus Diabetes Care. 10: 639-644. PMID 3315516 |
0.316 |
|
| Show low-probability matches. |